Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis

NCT00955279 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00955279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00955279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis
Lead sponsor
Centocor, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
August 31, 2012
Enrollment
173 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoidosis